Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats

被引:0
|
作者
Chu, XY [1 ]
Kato, Y [1 ]
Sugiyama, Y [1 ]
机构
[1] UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-II and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-II and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.
引用
收藏
页码:1934 / 1938
页数:5
相关论文
共 50 条
  • [11] Clinical pharmacogenetics of irinotecan (CPT-11)
    Ando, Y
    Hasegawa, Y
    DRUG METABOLISM REVIEWS, 2005, 37 (03) : 565 - 574
  • [12] Irinotecan (CPT-11): A brief overview
    Rivory, LP
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1996, 23 (10-11) : 1000 - 1004
  • [13] Clinical pharmacogenetics of irinotecan (CPT-11)
    Ando, Y
    DRUG METABOLISM REVIEWS, 2004, 36 : 16 - 16
  • [14] A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma
    Sanz-Altamira, PM
    O'Reilly, E
    Stuart, KE
    Raeburn, L
    Steger, C
    Kemeny, NE
    Saltz, LB
    ANNALS OF ONCOLOGY, 2001, 12 (04) : 501 - 504
  • [15] Liquid chromatographic determination of irinotecan (CPT-11) and its major metabolites in human plasma, urine and feces
    Sparreboom, A
    de Bruijn, P
    de Jonge, MJA
    Loos, WJ
    Nooter, K
    Stoter, G
    Verweij, J
    ANNALS OF ONCOLOGY, 1998, 9 : 58 - 58
  • [16] Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients
    Slatter, JG
    Schaaf, LJ
    Sams, JP
    Feenstra, KL
    Johnson, MG
    Bombardt, PA
    Cathcart, KS
    Verburg, MT
    Pearson, LK
    Compton, LD
    Miller, LL
    Baker, DS
    Pesheck, CV
    Lord, RS
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (04) : 423 - 433
  • [17] Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma
    Le, DT
    Deavers, M
    Hunt, K
    Malpica, A
    Verschraegen, CF
    CANCER INVESTIGATION, 2003, 21 (05) : 682 - 689
  • [18] Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
    Mathijssen, RHJ
    van Alphen, RJ
    Verweij, J
    Loos, WJ
    Nooter, K
    Stoter, G
    Sparreboom, A
    CLINICAL CANCER RESEARCH, 2001, 7 (08) : 2182 - 2194
  • [19] The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
    Dodds, HM
    Rivory, LP
    MOLECULAR PHARMACOLOGY, 1999, 56 (06) : 1346 - 1353
  • [20] Synthesis of CPT-11 (irinotecan hydrochloride trihydrate)
    Sawada, S
    Yokokura, T
    Miyasaka, T
    CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 : 13 - 28